Search
Close this search box.
Log In
CQMS
Make a Donation
Log In
Donate
Search
Close this search box.
Search
Close this search box.

TROG 20.03 – AVATAR

Open - In Follow Up
Breast

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

Primary Sponsor

Victorian Comprehensive Cancer Centre (VCCC)

Collaborating Groups

Trans-Tasman Radiation Oncology Group (TROG)

Accrual Target

32

Trial Chairperson

Dr Steven David, Peter MacCallum Cancer Centre, VIC

Prev Post

R2810-ONC-1788/TROG 17.11 – CPOST

Next Post

ICR-CTSU/2015/15552/TROG 16.03 – CORE

Related Post

TOPGEAR trial results published in the New England Journal of Medicine
18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

Join us to raise $35,000

Learn about the Trek4TROG Blue Mountains Bush Walk

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Facebook-f Twitter Youtube Instagram

Quick Links

Legalities

Latest News

Keep up to date with TROG news, subscribe to our community newsletter.

Subscribe

ABN:  45 132 672 292